Semax and Cerebrolysin are both neuro-focused compounds with roots in Russian and Eastern European clinical use, but they are very different in nature. Semax is a single, defined peptide (an ACTH fragment analog) given intranasally for focus and neuroprotection. Cerebrolysin is a complex mixture of peptides and amino acids derived from pig brain, given by injection and studied for stroke and dementia. Neither is FDA-approved.
At a glance
| Semax | Cerebrolysin | |
|---|---|---|
| What it is | Single defined peptide (ACTH 4–10 analog) | Brain-derived peptide/amino-acid mixture |
| Route | Intranasal | Injection (IV/IM) |
| Studied for | Focus, cognition, neuroprotection | Stroke, dementia, brain injury |
| Origin | Russia | Used in Russia and parts of Europe/Asia |
| FDA status | Not approved | Not approved |
| Western evidence | Limited independent trials | Mixed; some trials, debated |
The bottom line
Bottom line: Semax is a precise, single-molecule nootropic; Cerebrolysin is a complex biological mixture used clinically for serious neurological conditions in some countries. Both lack FDA approval and robust independent Western evidence, though Cerebrolysin has been studied in larger clinical settings (with debated results). They serve quite different purposes.
Frequently asked questions
What's the difference between Semax and Cerebrolysin?
Semax is a single, defined peptide given as a nasal spray for focus and neuroprotection, while Cerebrolysin is a complex mixture of peptides and amino acids derived from pig brain, given by injection for conditions like stroke and dementia.
Are Semax and Cerebrolysin FDA-approved?
No. Neither is FDA-approved. Both are used clinically in Russia and some other countries, but independent Western evidence is limited for Semax and mixed/debated for Cerebrolysin.
Which has more clinical evidence?
Cerebrolysin has been studied in larger clinical trials (for stroke and dementia, with debated results), whereas Semax rests on smaller, mostly Russian studies. Neither is approved in the US.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of ACTH(4-10), increases brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006. Peer-reviewed study
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in the acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1997. Peer-reviewed study
- Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progression in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005. Peer-reviewed study
- Liu R, Chen Y, Huang H, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025. Peer-reviewed study
- Sciacca MFM, Naletova I, Giuffrida ML, et al. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. ACS Chem Neurosci. 2022. Peer-reviewed study
- Glazova NY, Manchenko DM, Volodina MA, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. 2021. Peer-reviewed study
- Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023. Peer-reviewed study
- Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in vascular dementia: a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011. Peer-reviewed study
- Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019. Peer-reviewed study
- Ziganshina LE, Abakumova T, Hoyle CH. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2020. Peer-reviewed study
- Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2017. Peer-reviewed study
- Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert Rev Neurother. 2018. Peer-reviewed study